Multiple Myeloma Perspective

 
 
  • Multiple Myeloma: Taking Control   Experts at City of Hope discuss factors that affect choice of initial therapy in multiple myeloma, including election of early autologous stem cell transplant.
  • A 62-Year-Old Man Who Demands Testing: USMLE Question A 62-year-old man who has no acute complaints demands testing for multiple myeloma, due to his father's death. What do his test results show?
  • EHA 2018 Read clinically focused news coverage of key developments from EHA 2018
  • Multiple Myeloma: Options for Better Outcomes   Leading oncologists from the City of Hope Medical Center discuss targeted therapies and immunotherapies, including CAR T cells, that are redefining treatment of patients with relapsed multiple myeloma.
  • Quantifying Cancer Risk in Patients With Glomerular Diseases Dr Desai reviews a paper that presents a useful guide in quantifying cancer risk in patients with glomerular diseases.
  • Immunotherapy Combinations Show Promise for Blood Cancers Immunotherapy combinations hold great promise for treating hematologic cancers, but the approach is not without risk.
  • Multiple Myeloma: The Clone Wars   A growing understanding of normal cell biology and the evolving patterns of cancer clones is contributing to more individualized treatment in multiple myeloma.
  • Multiple Myeloma: On the Horizon   In "On the Horizon," the Mayo team reports on developments in immunotherapies and emerging techniques that are poised to change the management practices of multiple myeloma, including a discussion of how new insights in myeloma cell biology may ultimately cure this disease.
  • Infection Prophylaxis, Immune Therapies Lead ASH Myeloma Data   Dr S. Vincent Rajkumar discusses the most promising new treatments reported for multiple stages of myeloma at this year's ASH meeting.
  • Multiple Myeloma: Recurrent Dilemma   "Recurrent Dilemma" addresses the management of recurrent myeloma. The Mayo team and their patients comment on the challenges of treating and coping with side effects, and touch on the most difficult decision in this setting: when to stop therapy.
  • Top News From ASH 2017: Slideshow Hot topics include moving to newer oral anticoagulants for cancer patients with VTE, plus practice-changing results in chronic lymphocytic leukemia, multiple myeloma, and Hodgkin's lymphoma.
  • Multiple Myeloma: Relapse Options Rewritten   In "Relapse Options Rewritten," Drs Joseph Mikhael and Keith Stewart provide an overview of the expanded array of new agents--several with overlapping indications--and offer guidance in the selection of therapies for patients with early relapsed disease.
  • Multiple Myeloma: Individualizing Initial Therapy   The Mayo team emphasizes the importance of individualizing initial therapy in multiple myeloma, including the option of offering outpatient stem cell transplantation to select patients.
  • Safety With CAR T-Cell Therapy   Dr Stephan Grupp tells the 'inside story' of issues raised at the recent FDA Oncology Drug Advisory Committee meeting on CAR T-cell therapy.
  • European Hematology Association (EHA) 2017 Congress Read clinically focused news coverage of key developments from EHA 2017.
  • Managing the Unique Challenges of Opioids in Cancer Care Pain management is complex for cancer patients and survivors. Clinicians should expect to see more survivors who need help managing their cancer pain as treatments continue extending survival.
  • Joseph Mikhael: ASCO 2017 Takeaways in Myeloma Myeloma expert Joseph Mikhael discusses the studies at ASCO 2017 that affected his practice.
  • Multiple Myeloma: Taking Risk Into Account   'Taking Risk Into Account' focuses on the use of genetic testing to stratify patients' tumors as being at high, intermediate, or standard risk for progression, which allows clinicians to individualize treatment over the course of a patient's disease.
  • Multiple Myeloma: A Changing Landscape   Leading oncologists from the Mayo Clinic chart the optimal course through the changing therapeutic landscape of early relapsed multiple myeloma.
  • Cellular Immunotherapy for Multiple Myeloma Advancing Rapidly Multiple myeloma may be a singularly promising target for cellular immunotherapies, according to data presented at the most recent ASH annual meeting.